Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT ID: NCT04678206

Last Updated: 2021-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

310 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-07

Study Completion Date

2021-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to determine the therapeutic dose of BLU-5937 in patients with refractory chronic cough by assessing the change from baseline to week 4 in the 24-hour cough frequency with BLU-5937 relative to placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractory Chronic Cough

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

BLU-5937 Refractory Chronic Cough P2X3 receptor antagonist

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel Assignment
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BLU-5937 Dose A

BLU-5937 oral dose A twice a day.

Group Type EXPERIMENTAL

BLU-5937

Intervention Type DRUG

Oral administration of BLU-5937 Tablets

BLU-5937 Dose B

BLU-5937 oral dose B twice a day.

Group Type EXPERIMENTAL

BLU-5937

Intervention Type DRUG

Oral administration of BLU-5937 Tablets

BLU-5937 Dose C

BLU-5937 oral dose C twice a day.

Group Type EXPERIMENTAL

BLU-5937

Intervention Type DRUG

Oral administration of BLU-5937 Tablets

Placebo

Matching Placebo for BLU-5937 oral dose twice a day.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral administration of matching placebo for BLU-5937 Tablets

BLU-5937 Dose A (Population with baseline cough < 25 coughs/hour)

BLU-5937 oral dose A twice a day.

Group Type EXPERIMENTAL

BLU-5937

Intervention Type DRUG

Oral administration of BLU-5937 Tablets

Placebo (Population with baseline cough < 25 coughs/hour)

Matching Placebo for BLU-5937 oral dose twice a day.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral administration of matching placebo for BLU-5937 Tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BLU-5937

Oral administration of BLU-5937 Tablets

Intervention Type DRUG

Placebo

Oral administration of matching placebo for BLU-5937 Tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Capable of giving signed informed consent
* Refractory chronic cough (including unexplained chronic cough) for at least one year
* Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose

Exclusion Criteria

* Current smoker/vaper (all forms of smoking and inhaled substances, including , cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history
* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma
* Respiratory tract infection within 4 weeks before screening
* Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
* History of malignancy in the last 5 years
* History of alcohol or drug abuse within the last 3 years
* Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
* Previous participation in a BLU-5937 trial
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bellus Health Inc. - a GSK company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Phoenix Medical Research Inc

Peoria, Arizona, United States

Site Status

Little Rock Allergy and Asthma Clinical Research Center

Little Rock, Arkansas, United States

Site Status

Southern California Institute For Respiratory Diseases, Inc

Los Angeles, California, United States

Site Status

Allergy and Asthma Associates of Southern California

Mission Viejo, California, United States

Site Status

California Medical Research Associates, Inc.

Northridge, California, United States

Site Status

Allergy Associates Medical Group Inc.

San Diego, California, United States

Site Status

Allergy and Asthma Associates of Santa Clara Valley Research Center

San Jose, California, United States

Site Status

Colorado Allergy and Asthma Centers

Denver, Colorado, United States

Site Status

St. Francis Medical Institute

Clearwater, Florida, United States

Site Status

Floridian Clinical Research

Hialeah, Florida, United States

Site Status

Sweet Hope Research Specialty, Inc.

Hialeah, Florida, United States

Site Status

Sher Allergy Specialist/Center for Cough

Largo, Florida, United States

Site Status

Medical Research of Central Florida

Leesburg, Florida, United States

Site Status

ProCare Clinical Research

Miami Lakes, Florida, United States

Site Status

Central Florida Pulmonary Group PA

Orlando, Florida, United States

Site Status

Lenus Research & Medical Group

Sweetwater, Florida, United States

Site Status

IACT Health - Columbus

Columbus, Georgia, United States

Site Status

IACT Health - Lawrenceville

Lawrenceville, Georgia, United States

Site Status

IACT Health - Rincon

Rincon, Georgia, United States

Site Status

Sneeze Wheeze and Itch Associates LLC

Normal, Illinois, United States

Site Status

AES - Synexus Clinical Research US, Inc. - Evansville

Evansville, Indiana, United States

Site Status

Abraham Research PLLC

Fort Mitchell, Kentucky, United States

Site Status

Infinity Medical Research Inc

North Dartmouth, Massachusetts, United States

Site Status

Minnesota Lung Center

Edina, Minnesota, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Minnesota Lung Center

Woodbury, Minnesota, United States

Site Status

The Lung Research Center, LLC

Chesterfield, Missouri, United States

Site Status

University of Missouri, ENT and Allergy Center of Missouri

Columbia, Missouri, United States

Site Status

The Clinical Research Center LLC

St Louis, Missouri, United States

Site Status

Montana Medical Research

Missoula, Montana, United States

Site Status

Creighton University Medical Center

Omaha, Nebraska, United States

Site Status

Atlantic Respiratory Institute

Summit, New Jersey, United States

Site Status

Albuquerque Clinical Trials Inc

Albuquerque, New Mexico, United States

Site Status

CHEAR Center LLC

The Bronx, New York, United States

Site Status

American Health Research Inc

Charlotte, North Carolina, United States

Site Status

Clinical Research of Gastonia

Gastonia, North Carolina, United States

Site Status

Southeastern Research Center

Winston-Salem, North Carolina, United States

Site Status

Bernstein Clinical Research Center Inc

Cincinnati, Ohio, United States

Site Status

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Remington Davis Inc

Columbus, Ohio, United States

Site Status

Vital Prospects Clinical Research Institute PC

Tulsa, Oklahoma, United States

Site Status

Clinical Research Associates Of Central Pa

Altoona, Pennsylvania, United States

Site Status

Synexus Clinical Research US, Inc.

Anderson, South Carolina, United States

Site Status

National Allergy and Asthma Research

Charleston, South Carolina, United States

Site Status

Clinical Research of Rock Hill

Rock Hill, South Carolina, United States

Site Status

Clinical Trials Center of Middle Tennessee

Franklin, Tennessee, United States

Site Status

Pharmaceutical Research & Consulting Inc

Dallas, Texas, United States

Site Status

El Paso Pulmonary Association

El Paso, Texas, United States

Site Status

Village Research, LLC

Houston, Texas, United States

Site Status

Metroplex Pulmonary and Sleep Medicine Center

McKinney, Texas, United States

Site Status

Diagnostics Research Group

San Antonio, Texas, United States

Site Status

Sherman Clinical Research

Sherman, Texas, United States

Site Status

Allergy Asthma Research Institute

Waco, Texas, United States

Site Status

Intermountain Clinical Research

Draper, Utah, United States

Site Status

TPMG Lung & Sleep Specialist

Williamsburg, Virginia, United States

Site Status

McMaster University Medical Centre

Hamilton, Ontario, Canada

Site Status

Diex Recherche - Québec

Québec, Quebec, Canada

Site Status

Clinique Spécialisée en Allergie de la Capitale

Québec, Quebec, Canada

Site Status

Inspiration Research Limited

Toronto, Quebec, Canada

Site Status

C I C Maurice Inc

Trois-Rivières, Quebec, Canada

Site Status

Diex Recherche - Victoriaville

Victoriaville, Quebec, Canada

Site Status

MUDr. I. Cierná Peterová s.r.o.

Brandýs nad Labem-Stará Boleslav, Central Bohemia, Czechia

Site Status

Pneumologie Varnsdorf S.r.o.

Nový Bor, Liberec, Czechia

Site Status

Plicní ambulance Rokycany s.r.o.

Rokycany, Plzeň, Czechia

Site Status

Synexus Czech s.r.o.

Prague, Prague, Czechia

Site Status

MediTrial s.r.o.

Jindřichův Hradec, South Bohemia, Czechia

Site Status

MUDr. Jaroslav Mares - odborny lekar pro obor tuberkulosa a respiracni nemoci

Strakonice, South Bohemia, Czechia

Site Status

Plicni stredisko Teplice s.r.o.

Teplice, Ústí Nad Labem, Czechia

Site Status

Thoraxklinik-Heidelberg gGmbH

Heidelberg, Baden-Wurttemberg, Germany

Site Status

Synexus Frankfurt Research Centre

Frankfurt am Main, Hesse, Germany

Site Status

IKF Pneumologie

Frankfurt am Main, Hesse, Germany

Site Status

Zentrum für ambulante pneumologische Forschung Marburg GbR

Marburg, Hesse, Germany

Site Status

Ballenberger. Freytag. Wenisch - Institut fuer klinische Forschung GmbH

Neu-Isenburg, Hesse, Germany

Site Status

Kfns Klinische Forschung Schwerin

Schwerin, Mecklenburg-Vorpommern, Germany

Site Status

Universitätsklinikum Bonn

Bonn, North Rhine-Westphalia, Germany

Site Status

Klinische Forschung Dresden GmbH (KFGN)

Dresden, Saxony, Germany

Site Status

Synexus Leipzig Research Centre

Leipzig, Saxony, Germany

Site Status

Ärztezentrum Axel Springer Passage

Berlin, , Germany

Site Status

Da Vinci Maganklinika

Pécs, Baranya, Hungary

Site Status

Synexus Gyula - Magyarország Egészségügyi Szolgáltató Kft

Gyula, Bekes County, Hungary

Site Status

Dr. Kenessey Albert Korhaz-Rendelointezet

Balassagyarmat, Nógrád megye, Hungary

Site Status

Szent Borbála Kórház

Tatabánya, Nógrád megye, Hungary

Site Status

Synexus Zalaegerszeg Magyarország Egészségügyi Kft

Zalaegerszeg, Zala County, Hungary

Site Status

Synexus Budapest - Magyarország Egészségügyi Szolgáltató Kft

Budapest, , Hungary

Site Status

Osrodek Badan Klinicznych CLINSANTE S.C. Ewa Galczak-Nowak Malgorzata Trzaska

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Medical Center Kermed

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Centrum Medyczne Bydgoszcz - PRATIA

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z.o.o

Tarnów, Lesser Poland Voivodeship, Poland

Site Status

KLIMED

Bychawa, Lublin Voivodeship, Poland

Site Status

Clinical Best Solutions -Lublin

Lublin, Lublin Voivodeship, Poland

Site Status

Centrum Alergologii Specjalistyczna Przychodnia Alergologiczna

Lublin, Lublin Voivodeship, Poland

Site Status

Centrum Medyczne Warszawa - PRATIA

Warsaw, Masovian Voivodeship, Poland

Site Status

Prywatny Gabinet Internistyczno-Alergologiczny

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Gdansku

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Czestochowie

Częstochowa, Silesian Voivodeship, Poland

Site Status

Centrum Medyczne Wos i Piwowarczyk

Kraków, Łódź Voivodeship, Poland

Site Status

Synexus Polska Sp. Z o.o Oddzial w Lodzi

Lodz, Łódź Voivodeship, Poland

Site Status

Ostrowieckie Centrum Medyczne Spólka Cywilna Anna Olech-Cudzik, Krzysztof Cudzik

Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Poland

Site Status

Synexus Midlands Clinical Research Centre

Birmingham, England, United Kingdom

Site Status

West Walk Surgery

Bristol, England, United Kingdom

Site Status

MeDiNova Northamptonshire Quality Research Site

Corby, England, United Kingdom

Site Status

Castle Hill Hospital

Cottingham, England, United Kingdom

Site Status

MeDiNova Warwickshire Quality Research Site

Kenilworth, England, United Kingdom

Site Status

Kings College Hospital

London, England, United Kingdom

Site Status

Royal Brompton Hospital

London, England, United Kingdom

Site Status

NW Consortium Manchester

Manchester, England, United Kingdom

Site Status

Wythenshawe Hospital - PPDS

Manchester, England, United Kingdom

Site Status

MeDiNova North London Quality Research Site

Middlesex, England, United Kingdom

Site Status

North Tyneside General Hospital

North Shields, England, United Kingdom

Site Status

MeDiNova East London Quality Research Site

Romford, England, United Kingdom

Site Status

MeDiNova Yorkshire Quality Research Site

Shipley, England, United Kingdom

Site Status

MeDiNova South London Quality Research Site

Sidcup, England, United Kingdom

Site Status

MeDiNova West London Quality Research Site

Wokingham, England, United Kingdom

Site Status

Ormeau Clinical Trials Limited

Belfast, Northern Ireland, United Kingdom

Site Status

Belfast City Hospital

Belfast, Northern Ireland, United Kingdom

Site Status

AES - Synexus Scotland Clinical Research Centre

Glasgow, Scotland, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Czechia Germany Hungary Poland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Smith JA, Birring SS, Blaiss MS, McGarvey L, Morice AH, Sher M, Carroll KJ, Garin M, Lanouette S, Shaw J, Yang R, Bonuccelli CM. Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE). Am J Respir Crit Care Med. 2025 Jun;211(6):1038-1048. doi: 10.1164/rccm.202409-1752OC.

Reference Type DERIVED
PMID: 40043302 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-004136-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BUS-P2-02

Identifier Type: -

Identifier Source: org_study_id